

CONTINUING EDUCATION

as a part of



USE OF HYPOXIA-INDUCIBLE FACTOR PROLYL HYDROXYLASE INHIBITORS FOR THE TREATMENT OF ANEMIA OF CHRONIC KIDNEY DISEASE: WHAT HIF?

Sarah Edwards **Presenter:**

PGY-2 Pharmacotherapy Resident

UIW Feik School of Pharmacy, San Antonio, TX

Upon completion of this activity, pharmacists will be able to:

- 1. Identify the place in therapy of erythropoiesis-stimulating agents (ESA) for the treatment of anemia of chronic kidney disease (CKD) in patients undergoing hemodialysis (HD)
- 2. Recognize the black box warnings associated with erythropoiesis-stimulating agents (ESA)
- 3. Describe the effects of hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHI) on erythropoietin, hepcidin, and iron
- 4. Summarize current literature comparing the use of hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHI) to erythropoiesis-stimulating agents (ESA) for the treatment of anemia of chronic kidney disease (CKD) in patients undergoing hemodialysis (HD)
- 5. Given a patient case, select an appropriate treatment regimen for a patient with anemia of chronic kidney disease (CKD) undergoing hemodialysis (HD)

Upon completion of this activity, pharmacy technicians will be able to:

- 1. Recognize two generic erythropoiesis-stimulating agents (ESA)
- 2. Recognize the black box warnings associated with erythropoiesis-stimulating agents (ESA)
- 3. Recall the randomized control trials that evaluated the use of daprodustat in patients with anemia of chronic kidney disease (CKD) undergoing dialysis
- 4. Given a patient case, recognize the benefits of using hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHI) for the treatment of anemia of chronic kidney disease (CKD) in patients undergoing hemodialysis (HD)

evaluation form is completed and submitted through FSOP's Learning Express CE website (https://uiwfsop.learningexpressce.com/). For detailed instructions on how to use the site, see the link at www.uiw.edu/pharmacy/alumni/cpe.html. Participants will have six weeks to complete the post-test and evaluation form.

Friday, November 11, 2022 from 2:00-3:00 PM Date/Time:

Live Online Via Microsoft Teams Location:

FSOP 533 or Click to Join via Microsoft Teams Room:

The deadline to submit the post-test and evaluation form to obtain CE credit is December 23, 2022.

CPE Credit: 1.0 contact hours (UAN: 0445-0000-22-020-L01-P; 0445-0000-22-020-L01-T)

Activity Type: Application-based activity

Target Audience: Pharmacists and Pharmacy Technicians Fees:

RSVP: No RSVP required

No fees; activity is free-of-charge The University of the Incarnate Word Feik School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program is designed for pharmacists and pharmacy technicians to gain knowledge related to anemia of CKD. There are no fees for this application-based CPE program. The pharmacist or pharmacy technician will only receive credit for programs after receiving a 70% on a post-test and an activity

